ZepboundvsWegovy

Zepbound's active drug, tirzepatide, is a once-weekly injection that activates two gut-hormone receptors at once: GLP-1 and GIP. This "dual agonist" design is what sets it apart from GLP-1-only drugs like Wegovy. By mimicking these hormones, it curbs appetite, increases fullness, and slows how fast the stomach empties, so most people eat less and feel satisfied longer. It also improves how the body releases insulin and handles blood sugar. The result is sustained calorie reduction without the constant hunger that derails many diets.

Wegovy's active ingredient, semaglutide, mimics a natural gut hormone called GLP-1 (glucagon-like peptide-1). By activating GLP-1 receptors in the brain's appetite centers, it reduces hunger, increases feelings of fullness, and slows how quickly the stomach empties. The result is that most people naturally eat less and feel satisfied on smaller portions. It also improves how the body handles blood sugar. Because it does not "burn fat" directly, it works largely by lowering calorie intake, which is why diet and physical activity remain part of treatment.

In the pivotal 72-week SURMOUNT-1 trial (2,539 adults with obesity or overweight, without type 2 diabetes; published in the New England Journal of Medicine in 2022), tirzepatide produced average body-weight reductions of about 16.0% at 5 mg, 21.4% at 10 mg, and 22.5% at 15 mg, versus roughly 2.4% with placebo. In the head-to-head SURMOUNT-5 trial (751 participants, 72 weeks, NEJM 2025), Zepbound beat Wegovy (semaglutide) with an average 20.2% weight loss versus 13.7%, a 47% greater relative reduction; about 31.6% of Zepbound users lost at least 25% of their body weight versus 16.1% on Wegovy. Zepbound is also FDA-approved (December 2024) for moderate-to-severe obstructive sleep apnea in adults with obesity, where the SURMOUNT-OSA program showed clinically meaningful reductions in the apnea-hypopnea index versus placebo. Individual results vary with dose, diet, and activity.

In the pivotal STEP 1 trial (NEJM, 2021; 1,961 adults with overweight or obesity but without diabetes), weekly semaglutide 2.4 mg produced an average weight loss of about 14.9% of body weight at 68 weeks versus roughly 2.4% with placebo, and about 86% of treated participants lost at least 5% of their body weight. The 2-year STEP 5 trial (Nature Medicine, 2022) showed sustained results with continued use: about 15.2% mean weight loss versus 2.6% with placebo at 104 weeks. In the large SELECT cardiovascular outcomes trial (NEJM, 2023; 17,604 adults with established cardiovascular disease, overweight or obese, without diabetes), semaglutide reduced major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, non-fatal stroke) by 20% versus placebo (hazard ratio 0.80). The newer oral Wegovy 25 mg pill produced about 16.6% mean weight loss among participants who adhered to treatment in the OASIS 4 trial. Individual results vary.

The most common side effects are gastrointestinal and tend to appear during dose increases: nausea (reported in roughly 25-30% of users across the pivotal trials, and as high as the mid-30s in some studies), diarrhea, vomiting, constipation, abdominal pain, indigestion, and fatigue or injection-site reactions. These are usually mild-to-moderate and ease over time with slow titration, though they lead a small percentage of people to stop treatment. Less common but serious risks include pancreatitis (severe persistent abdominal pain), gallbladder problems including gallstones, acute kidney injury (often from dehydration due to vomiting or diarrhea), severe allergic reactions, and low blood sugar when combined with insulin or sulfonylureas. Zepbound carries an FDA boxed warning for thyroid C-cell tumors seen in rodent studies; whether it causes them in humans is unknown, but it is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2. Seek care promptly for severe stomach pain, signs of an allergic reaction, or vision changes.

The most common side effects (each occurring in 5% or more of users in trials) are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain, bloating, and indigestion, along with headache, fatigue, and dizziness. These are usually mild to moderate, tend to be worst when starting or increasing the dose, and often ease over a few weeks. Serious but less common risks include pancreatitis, gallbladder problems (including gallstones), acute kidney injury from dehydration caused by vomiting or diarrhea, low blood sugar (mainly in people also taking diabetes medications such as insulin or sulfonylureas), and worsening of diabetic eye disease. Wegovy carries a boxed warning for thyroid C-cell tumors based on rodent studies; whether this risk applies to humans is not known. Seek medical care promptly for severe, persistent abdominal pain (a possible sign of pancreatitis). This is not a complete list; review the full label and discuss risks with your prescriber.

As of September 2026, LillyDirect's regular self-pay price for a one-month Zepbound KwikPen supply is $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg and $699 for 10 mg, 12.5 mg or 15 mg; Lilly's Zepbound Journey Program can lower the higher-dose prices if you refill on schedule. Self-pay pricing can't be combined with insurance. With commercial insurance that covers Zepbound, Lilly's savings card can reduce the copay for eligible patients (monthly and annual caps apply). Coverage for weight loss varies by plan, so confirm your own benefits before starting, and budget for an ongoing monthly cost — it is a long-term medication.

As of September 2026, Wegovy's list price is $1,349.02 per package, but cash-paying patients rarely pay that: NovoCare's self-pay price is $349/month for the 0.25–2.4 mg pens and $399/month for Wegovy HD 7.2 mg, and new patients pay $199/month for their first two fills of 0.25 mg or 0.5 mg through December 31, 2026. The Wegovy pill has separate self-pay pricing starting at $149/month. With commercial insurance that covers Wegovy, the manufacturer savings card can lower the copay further for eligible patients, but many plans — and most Medicare and Medicaid plans — still exclude weight-loss drugs. Verify pricing for your dose with NovoCare before starting.

Zepbound is approved for adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) plus at least one weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes, and for moderate-to-severe obstructive sleep apnea in adults with obesity. It is meant to be used alongside a reduced-calorie diet and more physical activity. Do NOT use it if you or a family member has had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you have had a serious allergic reaction to tirzepatide. It is not for use in pregnancy and is not approved for children. Use caution with a history of pancreatitis, gallbladder disease, kidney problems, or severe gastrointestinal disease, and tell your doctor if you take insulin or sulfonylureas (which raise low-blood-sugar risk). Your prescriber makes the final eligibility call.

Wegovy is FDA-approved for adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) who also have a weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol, used alongside a reduced-calorie diet and increased physical activity. It is also approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease who are overweight or obese, and for adolescents aged 12 and older with obesity. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in those with a known serious allergy to semaglutide or any Wegovy ingredient. It should not be used during pregnancy; because of semaglutide's long half-life, the label advises stopping at least 2 months before a planned pregnancy. Use cautiously, and under close supervision, with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, kidney problems, or diabetic retinopathy. A clinician determines eligibility.